MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
ChromaDex Corporation Gross Profit 2011-2026 | CDXC
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit ChromaDex Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83.2 M | 61.6 M | 50.8 M | 42.8 M | 41.5 M | 35.3 M | 25.8 M | 16.1 M | 10.5 M | 8.48 M | 5.33 M | - | 3.13 M | 2.28 M | 2.94 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 83.2 M | 2.28 M | 27.8 M |
Quarterly Gross Profit ChromaDex Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.9 M | 20.2 M | 19.3 M | - | 16.2 M | 13.7 M | 13.5 M | - | 12 M | 12.4 M | 13.5 M | - | 10.2 M | 10 M | 10.5 M | - | 10.6 M | 10.8 M | 9.23 M | - | 8.45 M | 9.09 M | 8.31 M | - | 6.75 M | 6.25 M | 5.3 M | - | 4.36 M | 3.85 M | 3.14 M | 3.83 M | 2.92 M | 2.11 M | 1.62 M | 2.01 M | 1.86 M | 3.67 M | 2.84 M | 1.42 M | 2.48 M | 2.47 M | 1.93 M | - | 1.52 M | 1.4 M | 985 K | 749 K | 750 K | 961 K | 673 K | - | 1.25 M | 765 K | -604 K | - | 466 K | 581 K | 1.02 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.9 M | -604 K | 6.11 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
356 M | $ 21.81 | 1.87 % | $ 1.02 B |  USA |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-104 K | $ 0.91 | 1.61 % | $ 6.69 M |  China |
 |
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
473 M | $ 22.56 | 2.73 % | $ 3.74 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
225 M | $ 1.97 | 3.14 % | $ 409 M | USA |
 |
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
Heron Therapeutics
HRTX
|
114 M | $ 1.21 | 1.26 % | $ 202 M | USA |
 |
ImmuCell Corporation
ICCC
|
11.4 M | $ 8.22 | -1.56 % | $ 74.2 M | USA |
 |
InflaRx N.V.
IFRX
|
-7.24 M | $ 1.61 | 8.78 % | $ 152 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
Innate Pharma S.A.
IPHA
|
23.8 M | $ 1.4 | -1.06 % | $ 235 M | France |
 |
Aeterna Zentaris
AEZS
|
2.65 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aptinyx
APTX
|
1.56 K | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
5.68 K | - | -13.39 % | $ 1.45 M | USA |
 |
Jaguar Health
JAGX
|
6.1 M | $ 0.34 | -13.72 % | $ 793 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
1 K | - | 17.91 % | $ 11.1 M | USA |
 |
Aquestive Therapeutics
AQST
|
32.9 M | $ 4.12 | 0.86 % | $ 441 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
48.1 B | - | - | $ 96.9 B | Britain |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
109 M | $ 232.91 | 0.71 % | $ 4.26 B | USA |
 |
Eli Lilly and Company
LLY
|
17.6 B | $ 880.24 | -0.42 % | $ 790 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 2.92 | -0.34 % | $ 4.81 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
14 M | - | -4.8 % | $ 255 M | USA |